Analytical Data
-
Gene name
CHRNa2
- Application
-
Alternative Names
CHRNa2；Neuronal acetylcholine receptor subunit alpha-2
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q15822
-
Expression Region
1-529aa
-
AA Sequence
MGPSCPVFLSFTKLSLWWLLLTPAGGEEAKRPPPRAPGDPLSSPSPTALPQGGSHTETEDRLFKHLFRGYNRWARPVPNTSDVVIVRFGLSIAQLIDVDEKNQMMTTNVWLKQEWSDYKLRWNPTDFGNITSLRVPSEMIWIPDIVLYNNADGEFAVTHMTKAHLFSTGTVHWVPPAIYKSSCSIDVTFFPFDQQNCKMKFGSWTYDKAKIDLEQMEQTVDLKDYWESGEWAIVNATGTYNSKKYDCCAEIYPDVTYAFVIRRLPLFYTINLIIPCLLISCLTVLVFYLPSDCGEKITLCISVLLSLTVFLLLITEIIPSTSLVIPLIGEYLLFTMIFVTLSIVITVFVLNVHHRSPSTHTMPHWVRGALLGCVPRWLLMNRPPPPVELCHPLRLKLSPSYHWLESNVDAEEREVVVEEEDRWACAGHVAPSVGTLCSHGHLHSGASGPKAEALLQEGELLLSPHMQKALEGVHYIADHLRSEDADSSVKEDWKYVAMVIDRIFLWLFIIVCFLGTIGLFLPPFLAGMI
-
Molecular Weight
59.7 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The study of CHRNA2, a subtype of nicotinic acetylcholine receptors (nAChRs), is pivotal due to its significant role in neurophysiology and potential involvement in neurodegenerative diseases, psychiatric disorders, and addiction mechanisms. CHRNA2 is encoded by the CHRNA2 gene located on chromosome 8 and has been implicated in the modulation of neurotransmission and synaptic plasticity. Its unique structure and ligand-binding properties make it an attractive target for drug discovery and therapeutic interventions. Research has shown that alterations in CHRNA2 function can affect both cognitive processes and vulnerability to nicotine dependence. Moreover, the receptor's interaction with various biomolecules has prompted investigations into its role in diseases such as Alzheimer's and schizophrenia. The development of recombinant CHRNA2 proteins allows for detailed structural and functional studies, helping to elucidate the receptor's signaling pathways and interactions with other proteins. This foundational research has the potential to inform the development of novel pharmacological agents aimed at modulating CHRNA2 activity, ultimately contributing to the treatment of disorders linked to cholinergic dysfunction.
